It is an FDA-approved drug for chronic myeloid leukemia (CML) that showed promising outcomes in KIT-mutant PDX melanomas by comparing ponatinib to other RTK inhibitors [66]. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.